Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease
- PMID: 20386461
- DOI: 10.1097/YCT.0b013e3181c18a3d
Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease
Abstract
Objectives: Psychosis is common and often medically intractable in Parkinson disease (PD). Sometimes, its management is essential for the determination of the prognosis of PD. There have been several lines of studies demonstrating the effectiveness of electroconvulsive therapy (ECT) for depression in PD but very few for psychosis. The purpose of this retrospective study was to examine the effects of acute ECT on PD-associated psychosis.
Methods: The subjects were 5 elderly PD patients (duration, 2-10 years); 4 of whom were diagnosed as "other substance (antiparkinsonian medications)-induced psychotic disorder, with hallucinations," and as 1 "psychotic disorder due to PD, with hallucinations," according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Two patients had comorbidity of major depressive disorder, single episode. The psychosis, being refractory to antipsychotics, was treated with a course of acute ECT. Psychiatric conditions were evaluated using the Brief Psychiatric Rating Scale (BPRS), the Hamilton Depression Rating Scale (HDRS), and the Global Assessment of Functioning (GAF) scale. Motor function was assessed using the Hoehn and Yahr staging.
Results: The total BPRS and GAF scores after ECT improved significantly compared with those just before ECT. The Hoehn and Yahr staging also showed significant improvement. No marked adverse effects were seen. Duration of the improvement was between 5 and 30 weeks in followed-up patients.
Conclusions: Acute ECT was effective for medically refractory psychosis in patients with PD regardless of the comorbidity of depression. Our results suggest a possible indication of acute ECT for refractory psychosis in patients with PD.
Similar articles
-
Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy.Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1704-8. doi: 10.1016/j.pnpbp.2011.05.003. Epub 2011 May 12. Prog Neuropsychopharmacol Biol Psychiatry. 2011. PMID: 21605615 Clinical Trial.
-
[Maintenance electroconvulsive therapy and treatment of refractory schizophrenia].Encephale. 2008 Oct;34(5):526-33. doi: 10.1016/j.encep.2007.08.008. Epub 2008 Jan 11. Encephale. 2008. PMID: 19068343 French.
-
Comparative response to electroconvulsive therapy in medication-resistant bipolar I patients with depression and mixed state.J ECT. 2010 Jun;26(2):82-6. doi: 10.1097/YCT.0b013e3181b00f1e. J ECT. 2010. PMID: 19710623
-
Electroconvulsive therapy in Parkinson's disease.Arq Neuropsiquiatr. 2015 Oct;73(10):856-60. doi: 10.1590/0004-282X20150131. Epub 2015 Sep 1. Arq Neuropsiquiatr. 2015. PMID: 26331387 Review.
-
Using antipsychotic agents in older patients.J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. J Clin Psychiatry. 2004. PMID: 14994733 Review.
Cited by
-
Electroconvulsive Therapy in Psychiatric Disorders: A Narrative Review Exploring Neuroendocrine-Immune Therapeutic Mechanisms and Clinical Implications.Int J Mol Sci. 2022 Jun 22;23(13):6918. doi: 10.3390/ijms23136918. Int J Mol Sci. 2022. PMID: 35805923 Free PMC article. Review.
-
Noninvasive Therapies: A Forthcoming Approach to Parkinson's Treatment.CNS Neurol Disord Drug Targets. 2025;24(3):165-180. doi: 10.2174/0118715273318429240812094557. CNS Neurol Disord Drug Targets. 2025. PMID: 39225218 Review.
-
[Parkinson's disease and psychoses].Neuropsychiatr. 2015;29(1):1-13. doi: 10.1007/s40211-014-0132-8. Epub 2015 Jan 14. Neuropsychiatr. 2015. PMID: 25586068 Review. German.
-
Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis.World J Psychiatry. 2019 Jun 10;9(3):47-54. doi: 10.5498/wjp.v9.i3.47. eCollection 2019 Jun 10. World J Psychiatry. 2019. PMID: 31211112 Free PMC article.
-
Novel case of Parkinson's disease and schizophrenia: challenges in the management.BMJ Case Rep. 2021 Jul 29;14(7):e244028. doi: 10.1136/bcr-2021-244028. BMJ Case Rep. 2021. PMID: 34326119 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical